New Risk Model Can Help Guide Clinical Care for Endometrioid Endometrial Cancer

Research helps identify patients who might benefit from adjuvant therapies

20-WHI-1952612 CQD_Vaginal Estrogen_650x450_1175131340

Risk factors for endometrioid endometrial cancer (EC) have been widely studied, but no comprehensive model exists to predict survival and guide clinical care. Now a new study by Cleveland Clinic physicians establishes and validates an EC risk prediction model using a large data set from the National Cancer Database.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The study identifies factors that predict worse survival for EC, and helps identify which patients might benefit more from adjuvant therapies in early stage patients, a key question for which there have been no consistent guidelines to date, says Mariam M. AlHilli, MD, a surgeon in the Department of Obstetrics and Gynecology at Cleveland Clinic, and first author on the study. She says the model doesn’t create prescriptive guidelines, but can be used by clinicians to discuss treatment options.

“It’s a tool physicians can use when counseling patients,” she says. “They can look at different scenarios and give the patient an estimate of survival, and help the patient make decisions about whether to receive adjuvant treatment or not.”

The paper was recently published in the journal Gynecologic Oncology.

Endometrioid endometrial cancer is a common cancer with a generally good five-year survival rate of 83%. However, existing tools to predict survival had room for improvement.

“The treatment paradigm varies by geography and institution, and there is no clear consensus on who should be receiving adjuvant therapy in early stage disease,” AlHilli explains. “So a lot of times these decisions are made on an individual basis.”

For the study, researchers used a data set from the National Cancer Database involving more than 42,000 patients with endometrioid endometrial cancer.

“We wanted to see if we could select the most significant risk factors to triage patients to adjuvant therapy versus no adjuvant therapy,” she says.

Risk factors

They looked at a number of risk factors, and determined that factors associated with worse survival included:

  • being over age 60
  • being Black
  • having a Charlson-Deyo comorbidity score of 1 or 2+
  • having a higher grade of disease
  • having lymphovascular system invasion
  • having a tumor size larger than 2 cm
  • not having a lymphadectomy performed.

They also found that adjuvant therapy had a beneficial effect on survival in the majority of stage 1B patients, but only in one of the six risk groups in stage 1A.

Other groups have come up with similar risk prediction models, but the Cleveland Clinic study is the first to use the National Cancer Database and involve such a large cohort of patients, AlHilli says.

AlHilli’s team also validated their results with an internal cohort of patients at the Cleveland Clinic, she notes.

While the study did not bring a clear resolution as to which patients should receive adjuvant therapy, it does provide a framework for better decision-making, she says.

“The biggest take-home message is that there is a comprehensive and validated risk-scoring model that physicians can use to make a plan with their patients.”

Advertisement

Related Articles

Female cancer patient receiving chemotherapy
Adoptive Immunotherapy is Being Studied in Ovarian Cancer

Trial examines novel approach for a disease with a high mortality rate

Cervical cancer cells
Fertility-Sparing Management of Early-Stage Cervical Cancer

Studying trends of conization with lymph node evaluation, trachelectomy and radical hysterectomy

HIPEC
Could HIPEC Hold Promise for Advanced Endometrial Cancer?

Study showed that regimen was well-tolerated in cohort with aggressive carcinoma

Study Examines Factors Associated with Non-Completion of Intraperitoneal with Intravenous Chemotherapy in Women with Epithelial Ovarian Cancer
PARP Inhibitors Decrease Response to Subsequent Platinum-Based Chemotherapy in Recurrent Ovarian Cancer

Analysis suggests association between prior PARP inhibition and subsequent decreased progression-free survival in platinum-sensitive ovarian cancer

Fecal incontinence pessary
Vaginal Insert Offers Relief from Fecal Incontinence

Device provides alternative to conservative management and surgical procedures

translational-research_650x450
The Profound Impact of Philanthropy in Women’s Health Research

Announcing the Lilli and Seth Harris Endowed Chair for Ovarian Cancer

Ad